Most of the compounds have physiologically active properties, and their biological properties are often attributed to the heteroatoms contained in their molecules, and most of these heteroatoms also appear in cyclic structures. A Journal, Article, Cancer (Hoboken, NJ, United States) called The cumulative incidence of cisplatin-induced hearing loss in young children is higher and develops at an early stage during therapy compared with older children based on 2052 audiological assessments, Author is Meijer, Annelot J. M.; Li, Kathy H.; Brooks, Beth; Clemens, Eva; Ross, Colin J.; Rassekh, Sharad R.; Hoetink, Alex E.; van Grotel, Martine; van den Heuvel-Eibrink, Marry M.; Carleton, Bruce C., which mentions a compound: 41575-94-4, SMILESS is O=C1C2(CCC2)C(O[Pt]O1)=O.N.N, Molecular C6H12N2O4Pt, Synthetic Route of C6H12N2O4Pt.
Ototoxicity is a common adverse event of cisplatin treatment. The authors investigated the development of cisplatin-induced hearing loss (CIHL) over time in children with cancer by age and examined the influence of other clin. characteristics on the course of CIHL. Data from Canadian patients with childhood cancer were retrospectively reviewed. Hearing loss was graded according to International Society of Pediatric Oncol. criteria. The Kaplan-Meier method was applied to estimate the cumulative incidence of CIHL for the total cohort and according to age. Cox regression models were used to explore the effects of independent variables on CIHL development up to 3 years after the start of therapy. In total, 368 patients with 2052 audiol. assessments were included. Three years after initiating therapy, the cumulative incidence of CIHL was highest in patients aged ≤5 years (75%; 95% confidence interval [CI], 66%-84%), with a rapid increase observed to 27% (95% CI, 21%-35%) at 3 mo and to 61% (95% CI, 53%-69%) at 1 yr, compared with patients aged >5 years (48%; 95% CI, 37%-62%; P < .001). The total cumulative dose of cisplatin at 3 mo (per 100 mg/m2 increase: hazard ratio [HR], 1.20; 95% CI, 1.01-1.41) vincristine (HR, 2.87; 95% CI, 1.89-4.36) and the total duration of concomitantly administered antibiotics (>30 days: HR, 1.85; 95% CI, 1.17-2.95) further influenced CIHL development over time. In young children, the cumulative incidence of CIHL is higher compared with that in older children and develops early during therapy. The course of CIHL is further influenced by the total cumulative dose of cisplatin and other ototoxic (co-)medication. These results highlight the need for audiol. monitoring at each cisplatin cycle.
As far as I know, this compound(41575-94-4)Synthetic Route of C6H12N2O4Pt can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics